Camille Poirot

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortés et al. · Clinical Cancer Research · 2019 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, Michael P. Rettig, Norbert Vey et al. · Blood · 2018 · 39 citations

Medicine, Oncology, Pharmacology +17

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Gail J. Roboz, Marina Konopleva et al. · Blood · 2020 · 23 citations

Life Sciences, Hematology, Immunology +17

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Mario Campone, Thomas Bachelot, Frédérique Penault‐Llorca et al. · Cancer Chemotherapy and Pharmacology · 2019 · 19 citations · Full text

Medicine, Oncology, Pharmacology +16

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Piérola et al. · Blood · 2023 · 15 citations

Life Sciences, Immunology, Oncology +16